MedTrace Logo

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

NCT01872598 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 721

Last updated 2023-09-29

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of masitinib for the treatment of mild to moderate Alzheimer's Disease. Masitinib will be administered as add-on therapy in patients who have been treated for a minimum of 6 months with a stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Masitinib

DRUG

Placebo

DRUG

Standard of care

stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Bruno DUBOIS, M.D., Ph.D. · Pitié-Salpétrière

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Bulgaria
  • Greece
  • Poland
  • Romania
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01872598 on ClinicalTrials.gov